Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : US Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD).
Product Name : Esbriet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2021
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Propeller Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis’ asthma triple heads CHMP’s latest meeting
Details : Decision supported by robust efficacy and safety data from Phase III IRIDIUM study, in which once-daily Enerzair® Breezhaler® resulted in statistically significant improvements in lung function.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Propeller Health
Deal Size : Inapplicable
Deal Type : Inapplicable